Pfizer CEO says omicron appears milder but spreads faster and could lead to more Covid mutations
- "I don't think it's good news to have something that spreads fast," Pfizer CEO Albert Bourla told The Wall Street Journal.
- "Spreads fast means it will be in billions of people and another mutation may come. You don't want that," Bourla said.
- Bourla cautioned that it is difficult to draw definitive conclusions from the wave of infection in South Africa right now.
Pfizer CEO Albert Bourla on Tuesday said the omicron variant of the virus that causes Covid-19 appears to be milder than previous strains, but also seems to spread faster and could lead to more mutations in the future.
"I don't think it's good news to have something that spreads fast," Bourla told The Wall Street Journal during an interview at the paper's CEO Council Summit. "Spreads fast means it will be in billions of people and another mutation may come. You don't want that."
White House chief medical advisor Dr. Anthony Fauci said reports over the weekend from South Africa suggest omicron is not as severe as initially feared, while noting that more data is needed to fully assess the risk posed by the variant.
The South African Medical Research Council, in a report released on Saturday, said most patients admitted to a hospital in Pretoria who had Covid didn't need supplemental oxygen. The report also noted that many patients were admitted for other medical reasons and were then found to have Covid.
Bourla cautioned that it is difficult to draw definitive conclusions from the wave of infection in South Africa right now. Just 5% of South Africans are over the age of 60, and younger people normally have milder cases of Covid. However, many people in South Africa are also HIV positive, which would presumably lead to more severe disease from Covid, he said.
CNBC Health & Science
Read CNBC's latest global coverage of the Covid pandemic:
WHO wades into vaccine mandates dispute, saying they should be an 'absolute last resort'
WHO strongly advises against convalescent plasma for treating Covid patients
Ford delays return-to-work hybrid program until March amid omicron variant
New York City imposes vaccine mandate for all private sector employers, Mayor de Blasio says
U.S. is changing the rules for international travel because of omicron. Here's what you need to know
First data on Covid omicron variant's severity is 'encouraging,' Fauci says
The Pfizer CEO said he expects the number of confirmed omicron cases to surge from dozens to millions over the next few weeks.
"We will have a good understanding let's say before the year end as to what exactly it means for clinical manifestation," Bourla said.
Pfizer can develop a vaccine that targets omicron by March 2022, Bourla said, but it's not clear yet whether there's a need for a new shot. It will take a few weeks to determine whether the current vaccines provide enough protection against the variant, he said.
Bourla said Pfizer is confident that its oral antiviral medication, Paxlovid, will fight omicron and every other variant of the virus that has emerged so far. The pill inhibits an enzyme the virus needs to replicate, known as a protease.
Most of the virus' mutations have occurred on the spike protein so far, the mechanism it uses to attach to human cells, Bourla said. Vaccines and antibody treatments that target the spike protein may need updates when mutations occur on that part of the virus, he said.
However, it's much more difficult for the virus to mutate in a way where it can live without the protease enzyme that Paxlovid targets, he said.
"It's very difficult for the virus to create a strain that can live without this protease," Bourla said. "It's not impossible. It's very difficult."
Source: Read Full Article